CTIS2023-505839-12-01进行中（未招募）1 期
BIomarker-dRiven Dosing Interval Extension of biologics in asthma (the BIRDIE trial)
Sint Franciscus Vlietland Groep Stichting0 个研究点目标入组 114 人开始时间: 2023年6月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Severe asthma as primary indication for treatment with mepolizumab (one dose every 4 weeks) or dupilumab (one dose every 2 weeks) for the last 6 months., Stable asthma (an ACQ <1.5 and no severe asthma exacerbations) for at least 6 months., Sufficient understanding of the Dutch language
排除标准
- •Treatment with maintenance OCS, defined as treatment with OCS during 14 or more subsequent days, in the last 6 months, Treatment with immunosuppressants (other than mepolizumab, dupilumab or corticosteroids) in the last 6 months, Treatment with, or switching between, other biologics than the drug of interest in the 6 months before inclusion., Pulmonary disease(s) other than asthma (including EGPA), Pregnancy
研究者
相似试验
进行中（未招募）
1 期
Biomarker driven treatment for patients less than 65 years with aggressive B-cell lymphomaEUCTR2015-002846-30-FIHUS-The Hospital District of Helsinki and Uusimaa120
已完成
不适用
A Dose-Finding and Longitudinal Biomarker Study of Rhinovirus Challenge in Healthy Volunteers and Mild-Moderate Asthmatics to Evaluate the Safety and Use of a Human Rhinovirus Preparation in Developing High Dimensionality Phenotypes (*Handprints*) for Asthmadyspnearespiratory disease10006436asthmaNL-OMON41599Merck Sharp & Dohme (MSD)49
进行中（未招募）
1 期
what dose of vitamin D is the right one trialperioperative inflammation in patients undergoing oesophagectomy.EUCTR2011-004199-12-GBniversity of Birmingham18
进行中（未招募）
1 期
A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1ß Monoclonal Antibody (ACZ885) Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA) - CACZ885A2203Systemic Juvenile Idiopathic Arthritis (SJIA)MedDRA version: 8.1 Level: PT Classification code 10059177 Term: Juvenile arthritisEUCTR2006-001834-42-GBovartis Pharma Services AG26
已完成
2 期
A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1β Monoclonal Antibody (ACZ885) Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA)Joint inflammation with childrenSystemic Juvenile Idiopathic Arthritis (SJIA)10010761NL-OMON30805ovartis6